The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1089
October 2, 2000
View Complete Issue         Table of Contents 2019 
Eflornithine Cream For Facial Hair Reduction
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Eflornithine Cream For Facial Hair Reduction
October 2, 2000 (Issue: 1089)
Eflornithine hydrochloride cream 13.9% (Vaniqa - Bristol-Myers Squibb) has been approved by the FDA for reduction of unwanted facial hair in women.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Eflornithine Cream For Facial Hair Reduction
Article code: 1089c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.